tiprankstipranks
Advertisement
Advertisement

IMNM Stock Latest News

Immunome shareholders reaffirm board, auditor and pay policies
Company AnnouncementsImmunome shareholders reaffirm board, auditor and pay policies
4d ago
8K
IMNM
Charles Zhu Doubles Immunome Price Target to $40 on ADC Pipeline Progress and Favorable Risk‑Reward Profile
PremiumRatings
Charles Zhu Doubles Immunome Price Target to $40 on ADC Pipeline Progress and Favorable Risk‑Reward Profile
5d ago
IMNM
Immunome announces first patient dosed in Phase 1 trial of IM-1617
PremiumThe Fly
Immunome announces first patient dosed in Phase 1 trial of IM-1617
6d ago
IMNM
Immunome Reaffirmed at Buy as Varegacestat Data Underscore Competitive Edge; $40 Price Target Maintained
PremiumRatings
Immunome Reaffirmed at Buy as Varegacestat Data Underscore Competitive Edge; $40 Price Target Maintained
16d ago
IMNM
Immunome announces Ringside trial met primary, secondary endpoints
PremiumThe Fly
Immunome announces Ringside trial met primary, secondary endpoints
16d ago
IMNM
Immunome price target raised to $37 from $36 at Truist
PremiumThe FlyImmunome price target raised to $37 from $36 at Truist
19d ago
IMNM
Immunome initiated with an Overweight at Barclays
Premium
The Fly
Immunome initiated with an Overweight at Barclays
20d ago
IMNM
Immunome Expands Oncology Pipeline With New Phase 1 IM-1617 Trial
Premium
Company Announcements
Immunome Expands Oncology Pipeline With New Phase 1 IM-1617 Trial
25d ago
IMNM
Immunome price target lowered to $33 from $37 at Leerink
PremiumThe Fly
Immunome price target lowered to $33 from $37 at Leerink
1M ago
IMNM
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
PremiumRatings
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
1M ago
IMNM
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
PremiumRatings
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
1M ago
IMNM
Immunome reports Q1 EPS (48c), consensus (54c)
PremiumThe Fly
Immunome reports Q1 EPS (48c), consensus (54c)
1M ago
IMNM
Immunome announces submission of NDA for varegacestat in desmoid tumors
PremiumThe FlyImmunome announces submission of NDA for varegacestat in desmoid tumors
2M ago
IMNM
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
Premium
The Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
2M ago
GILD
IMNM
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
Premium
Ratings
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
3M ago
IMNM
Immunome price target lowered to $30 from $32 at Lake Street
PremiumThe Fly
Immunome price target lowered to $30 from $32 at Lake Street
3M ago
IMNM
Immunome price target raised to $36 from $33 at Craig-Hallum
PremiumThe Fly
Immunome price target raised to $36 from $33 at Craig-Hallum
3M ago
IMNM
Immunome price target lowered to $30 from $33 at Stephens
PremiumThe Fly
Immunome price target lowered to $30 from $33 at Stephens
3M ago
IMNM
Immunome price target raised to $39 from $35 at JPMorgan
PremiumThe Fly
Immunome price target raised to $39 from $35 at JPMorgan
3M ago
IMNM
Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
PremiumRatingsImmunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
3M ago
IMNM
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
Premium
The Fly
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
4M ago
IMNM
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
Premium
Ratings
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
4M ago
IMNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >